1. Number of participants with most often occurring serious adverse events during treatment.
| Trial | Gastrointestinal haemorrhage | Hepatorenal syndrome (with or without hepatic failure) | Septicaemia | Hepatocellular carcinoma | ||||
| Prednisolone | Control | Prednisolone | Control | Prednisolone | Control | Prednisolone | Control | |
| Helman 1971 | — | — | — | 3 | — | — | — | — |
| Porter 1971 | 4 | 2 | — | — | — | — | — | — |
| Campra 1973 | 3 | 5 | — | 4 | — | — | — | — |
| Blitzer 1977 | 3 | 2 | — | 2 | 2 fungal | — | — | 1 |
| Mendenhall 1977 | Not reported | — | — | — | — | — | — | — |
| Maddrey 1978 | 1 | 1 | 3 | 6 | — | — | — | — |
| Shumaker 1978 | 3 | 3 | — | — | 2 | — | — | |
| Depew 1980 | 2 | 1 | — | — | 2 | 1 | — | — |
| Theodossi 1982 | 11 | 6 | — | — | 7 | 6 | — | — |
| Bories 1987 | 3 | 3 | — | 2 | — | — | — | — |
| Carithers 1989 | 2 | 4 | — | — | 1 | — | — | — |
| Mendenhall 1984 | — | — | — | — | — | — | — | 2 |
| Ramond 1992 | 1 | 2 | — | — | 1 | 1 | — | — |
| De 2014 | 2 | 3 | 3 | — | 3 | 1 | — | — |
Richardet 1993 is missing from the table as no data were provided for quantitative analysis.
For Thursz 2015, see Table 3.